Jeremy Hill, MD
Neuromuscular Medicine · Greensboro, NCNPI 1144725003
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 96.2% of the total across 123 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 36 manufacturers, the largest accounting for just 15.1% — the pattern of someone who eats at a lot of different presentations. 2025 is the largest year on record at $1,171, 9.2 times the $128 reported in 2022.
Across 123 payments — averaging $22.65 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$419
- AbbVie$319
- UCB, Inc.$316
- Argenx US, Inc.$225
- Alnylam Pharmaceuticals Inc.$215
- Neurelis, Inc.$106
- plus $1K from 30 others
What the payments were for
- Food & beverage$2,68196%
- Education$1054%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca(2 entities) | 18 | $419 |
| AbbVie | 17 | $319 |
| UCB, Inc. | 13 | $316 |
| Argenx US, Inc. | 11 | $225 |
| Alnylam Pharmaceuticals Inc. | 6 | $215 |
| Neurelis, Inc. | 5 | $106 |
| Jazz Pharmaceuticals Inc. | 4 | $90 |
| EMD Serono, Inc. | 2 | $73 |
| Banner Life Sciences, LLC | 3 | $67 |
| Pfizer | 3 | $65 |
| Octapharma USA, Inc. | 3 | $65 |
| Mallinckrodt Hospital Products Inc. | 2 | $63 |
| TG Therapeutics, Inc. | 2 | $58 |
| Lundbeck LLC | 2 | $53 |
| Lilly USA, LLC | 3 | $52 |
| Amgen | 2 | $45 |
| Otsuka America Pharmaceutical, Inc. | 2 | $44 |
| Neurocrine Biosciences, Inc. | 2 | $43 |
| Medtronic | 2 | $42 |
| Genentech USA, Inc. | 2 | $40 |
| Biogen | 2 | $40 |
| GE HealthCare | 2 | $38 |
| Aucta Pharmaceuticals, Inc. | 2 | $34 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $34 |
| C2n Diagnostics, LLC | 1 | $25 |
| Amneal Pharmaceuticals LLC | 1 | $24 |
| Eisai Inc. | 1 | $22 |
| Catalyst Pharmaceuticals, Inc. | 1 | $21 |
| Kedrion Biopharma, Inc. | 1 | $21 |
| Johnson & Johnson | 1 | $21 |
| CSL Behring | 1 | $21 |
| Bristol Myers Squibb | 1 | $20 |
| Axsome Therapeutics, Inc. | 1 | $19 |
| SK Life Science, Inc. | 1 | $17 |
| Impel Pharmaceuticals Inc. | 1 | $15 |
| Kyowa Kirin, Inc. | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
Too few neuromuscular medicine providers in North Carolinato place this figure against a meaningful peer group, so we don't.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Duloxetine Hcl | 70 | $1,767 |
| Gabapentin | 99 | $1,737 |
| Pyridostigmine Bromide | 11 | $938 |
| Mycophenolate Mofetil | 22 | $693 |
| Pregabalin | 64 | $663 |
| Prednisone | 46 | $370 |
| Carbidopa-LevodopaCarbidopa/Levodopa | 18 | $330 |
| Primidone | 19 | $310 |
| Clonazepam | 23 | $259 |
| Nortriptyline Hcl | 18 | $202 |
| Lansoprazole | 12 | $194 |
| Topiramate | 14 | $132 |
| Propranolol Hcl | 17 | $98 |
| Sumatriptan Succinate | 12 | $63 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Amneal Pharmaceuticals LLCPyridostigmine Bromide, Mycophenolate Mofetil | $24 | $1,63033 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. There are too few neuromuscular medicine providers in North Carolinaon file to place this against a meaningful peer group, so we don't.
Other neuromuscular medicine in Greensboro
- Alyson HommelWilmington$76K
- Marisa McGheeWinston Salem$36K
- Anahit MehrabyanChapel Hill$10K
- Shruti RajaDurham$8K
- Jonathan MorenaDurham$3K
- Sandra TorresWilmington$2K
- Leslie Higuita MontoyaRaleigh$425
- Tiffany Pike-LeeFort Bragg$288
- Jordan MayberryDurham$281
- Araya PuwanantWinston-Salem$163
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.